VBL

VBL is harnessing novel biology in innovative ways, through cutting edge therapies, for unmet medical needs in cancer and chronic immune-inflammatory diseases. Our product pipeline is led by VB-111, a first-in-class anti-cancer gene therapy with a dual mechanism of action, that is in clinical development to treat a wide range of solid tumors... VBL has also developed Lecinoxoids, which are a novel class of investigational orally available anti-inflammatory small molecules that mimic the structure of native phospholipid molecules that regulate the inflammatory process. VBL is developing VB-201, which has demonstrated clinical proof-of-concept in a Phase 2 trial in vascular inflammation and is being evaluated as a treatment for severe COVID-19... We work to help people live better, longer lives. By harnessing novel biology, we deliver first-class therapeutics that increase survival rates and gives people time.

Primary location: Modi'in Israel